Int J Stomatol

Inter J Stomatol ›› 2018, Vol. 45 ›› Issue (2): 140-144.doi: 10.7518/gjkq.2018.02.004

• Oral Medicine • Previous Articles     Next Articles

Adverse reactions of targeted anticancer agents in oral cavity: manifestation and management

Xiao Yandi, Yang Huamei, Dan Hongxia   

  1. State Key Laboratory of Oral Diseases &National Clinical Research Center for Oral Diseases &Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2017-09-14 Revised:2017-12-27 Online:2018-03-01 Published:2018-03-01
  • Supported by:
    Specific Fund of National Health and Family Planning Commission of China (201502018) and National Key Clinical Program on Oral Mucosal Diseases in China (2014).

RichHTML

14

PDF (PC)

457

Abstract: Targeted therapy is widely used in cancer treatment. However, anticancer agents used in targeted therapy can induce various adverse reactions in oral cavity. This review aims to summarize the adverse reactions in oral cavity incurred during targeted therapy and the corresponding strategies for their management.

Key words: targeted agents, anticancer therapy, oral cavity, adverse drug reactions, managing strategies

CLC Number: 

  • R781.5

TrendMD: 
[1] Common terminology criteria for adverse events (CTCAE) version 4.0[S]. Bethesda: National Insti-tutes of Health, National Cancer Institute, 2009.
[2] Vigarios E, Epstein JB, Sibaud V.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors[J]. Support Care Can-cer, 2017, 25(5):1713-1739.
[3] Yuan A, Woo SB.Adverse drug events in the oral cavity[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 119(1):35-47.
[4] Shameem R, Lacouture M, Wu S.Incidence and risk of high-grade stomatitis with mTOR inhibitors in can-cer patients[J]. Cancer Invest, 2015, 33(3):70-77.
[5] Vargo CA, Berger MJ, Phillips G, et al.Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer[J]. Support Care Cancer, 2016, 24(7):2913-2918.
[6] Rugo HS, Hortobagyi GN, Yao J, et al.Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy[J]. Ann Oncol, 2016, 27(3):519-525.
[7] Kaplan B, Qazi Y, Wellen JR.Strategies for the ma-nagement of adverse events associated with mTOR inhibitors[J]. Transplant Rev (Orlando), 2014, 28(3): 126-133.
[8] Soria JC, Felip E, Cobo M, et al.Afatinib versus erlo-tinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2015, 16(8):897-907.
[9] Park K, Tan EH, O’Byrne K, et al. Afatinib versus ge-fitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J]. Lancet Oncol, 2016, 17(5):577-589.
[10] Burotto M, Manasanch EE, Wilkerson J, et al.Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials[J]. Oncologist, 2015, 20(4):400-410.
[11] Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19):1803-1813.
[12] Yamany T, Levender M, Silvers DN, et al.Erythema multiforme-like reaction with mucosal involvement following administration of idelalisib for relapse of chronic lymphocytic leukemia[J]. Leuk Lymphoma, 2015, 56(6):1872-1873.
[13] Edwards D, Boritz E, Cowen EW, et al.Erythema multiforme major following treatment with infliximab[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(2):e36-e40.
[14] Lowndes S, Darby A, Mead G, et al.Stevens-Johnson syndrome after treatment with rituximab[J]. Ann Oncol, 2002, 13(12):1948-1950.
[15] Peterson DE, O’Shaughnessy JA, Rugo HS, et al. Oral mucosal injury caused by mammalian target of rapa-mycin inhibitors: emerging perspectives on pathobio-logy and impact on clinical practice[J]. Cancer Med, 2016, 5(8):1897-1907.
[16] Kuten-Shorrer M, Hochberg EP, Woo SB.Lichenoid mucosal reaction to rituximab[J]. Oncologist, 2014, 19(10):e12-e13.
[17] Zhang JA, Yu JB, Li XH, et al.Oral and cutaneous lichenoid eruption with nail changes due to imatinib treatment in a chinese patient with chronic myeloid leukemia[J]. Ann Dermatol, 2015, 27(2):228-229.
[18] Luo JR, Xiang XJ, Xiong JP.Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor[J]. Int J Clin Pharmacol Ther, 2016, 54(9):719-722.
[19] Bloom MD, Gibney JM, Heldermon CD.Pigmentation of the tongue with lapatinib treatment in a patient with advanced breast cancer: a case report[J]. Cancer Treat Commun, 2016, 7:1-3.
[20] Khoo TL, Catalano A, Supple S, et al.Hyperpigmen-tation of the hard palate associated with imatinib the-rapy for chronic myeloid leukemia with a genetic va-riation in the proto-oncogene c-KIT[J]. Leuk Lym-phoma, 2013, 54(1):186-188.
[21] Li CC, Malik SM, Blaeser BF, et al.Mucosal pigmenta-tion caused by imatinib: report of three cases[J]. Head Neck Pathol, 2012, 6(2):290-295.
[22] Ellis PM, Shepherd FA, Millward M, et al.Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial[J]. Lancet Oncol, 2014, 15(12):1379-1388.
[23] Rizvi NA, Mazières J, Planchard D, et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squa-mous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial[J]. Lancet Oncol, 2015, 16(3):257-265.
[24] Robert C, Schachter J, Long GV, et al.Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372(26):2521-2532.
[25] Boer CC, Correa ME, Miranda EC, et al.Taste dis-orders and oral evaluation in patients undergoing allo-geneic hematopoietic SCT[J]. Bone Marrow Transplant, 2010, 45(4):705-711.
[26] Robert C, Long GV, Brady B, et al.Nivolumab in previously untreated melanoma without BRAF muta-tion[J]. N Engl J Med, 2015, 372(4):320-330.
[27] Tang N, Ratner D.Managing cutaneous side effects from targeted molecular inhibitors for melanoma and nonmelanoma skin cancer[J]. Dermatol Surg, 2016, 42(Suppl 1):S40-S48.
[28] Gavrilovic IT, Balagula Y, Rosen AC, et al.Charac-teristics of oral mucosal events related to bevacizu-mab treatment[J]. Oncologist, 2012, 17(2):274-278.
[29] Hubiche T, Valenza B, Chevreau C, et al.Geographic tongue induced by angiogenesis inhibitors[J]. Oncologist, 2013, 18(4):e16-e17.
[30] Rosen AC, Gavrilovic IT, Balagula Y, et al.In reply[J]. Oncologist, 2013, 18(4):e18.
[1] Pan Jian, Zhang Zhuang.. Complications of oral local anesthesia and their preventive treatments [J]. Inter J Stomatol, 2012, 39(2): 141-144.
[2] Chen Zhe1, Wang Jing2, Wang Hu3.. The music therapy in the field of oral treatment [J]. Inter J Stomatol, 2011, 38(6): 734-737.
[3] ZHAO Fang, LIU Dong-xu. Application of functional magnetic resonance imaging in stomatology [J]. Inter J Stomatol, 2009, 36(5): 586-589.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .